dc.contributor.author | Çevik, Mehtap | |
dc.contributor.author | Namal, Esat | |
dc.contributor.author | Iner-Koksal, Ulkuhan | |
dc.contributor.author | Dinc-Sener, Nur | |
dc.contributor.author | Karaalp, Atila | |
dc.contributor.author | Ciftci, Cavlan | |
dc.contributor.author | Susleyici, Belgin | |
dc.date.accessioned | 2022-11-04T19:55:27Z | |
dc.date.available | 2022-11-04T19:55:27Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 0301-4851 | |
dc.identifier.issn | 1573-4978 | |
dc.identifier.uri | https://doi.org/10.1007/s11033-021-06992-9 | |
dc.identifier.uri | http://hdl.handle.net/11446/4528 | |
dc.description.abstract | Background Programmed Cell Death-1 (PD-1) together with Programmed Death Ligand 1 (PDL-1) have crucial roles in anti-tumor immune response, cancer susceptibility and prognosis. Since PD-1 and PDL-1 have been considered as important genetic risk factors in cancer development and their functions can be affected by polymorphic sites, we investigated the effects of PD-1 rs2227981, rs2227982, rs36084323 and PDL-1 rs2282055, rs822336 gene polymorphisms on colorectal cancer (CRC) risk and prognosis in Turkish subjects. Methods and results Our study group consisted of 5-FU or Capacitabine prescribed CRC diagnosed patients and healthy controls. Genotype analyses of PD1 and PDL-1 polymorphisms were performed with Agena MassARRAY platform. rs36084323 CT genotype frequency was found to be higher in controls compared to cases (p < 0.001). rs36084323 CT genotype was highly associated with reduced CRC risk compared to CC genotype (OR 0.068, 95% CI 0.022-0.211, p < 0.001). In adjusted analysis, rs2282055 GG genotype was found to be associated with reduced CRC risk (OR 0.271, 95% CI 0.078-0.940, p = 0.040). rs2282055 TT genotype was found to be related to longer progression-free (Bonferroni corrected Log rank p = 0.013) and overall survival (Bonferroni corrected Log rank p = 0.009) to that of GG genotypes. Patients with rs822336 GC+CC genotypes showed longer overall survival times compared to GG (Log rank p = 0.044). Conclusions According to our results, PD-1 rs822336 G > C polymorphism might be useful in predicting CRC prognosis. PDL-1 rs2282055 T > G polymorphism might be useful in predicting both CRC risk and prognosis. Further studies should be conducted in larger and different populations to clear the roles of PD-1 and PDL-1 polymorphisms in CRC risk and prognosis. | en_US |
dc.description.sponsorship | Marmara University Scientific Research Projects Coordination Unit [FEN-C-DRP-110718-0407] | en_US |
dc.description.sponsorship | This study was supported by Marmara University Scientific Research Projects Coordination Unit. Project No. FEN-C-DRP-110718-0407. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.relation.ispartof | Molecular Biology Reports | en_US |
dc.identifier.doi | 10.1007/s11033-021-06992-9 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Colorectal cancer | en_US |
dc.subject | Immune check point | en_US |
dc.subject | PD-1 | en_US |
dc.subject | PDL-1 | en_US |
dc.subject | rs36084323 | en_US |
dc.subject | rs822336 | en_US |
dc.subject | rs2282055 | en_US |
dc.subject | Cell Lung-Cancer | en_US |
dc.subject | Induced Expression | en_US |
dc.subject | Immune Escape | en_US |
dc.subject | Breast-Cancer | en_US |
dc.subject | Tumor-Cells | en_US |
dc.subject | Pd1 Gene | en_US |
dc.subject | Susceptibility | en_US |
dc.subject | Pd-1/Pd-L1 | en_US |
dc.subject | Children | en_US |
dc.subject | Pathway | en_US |
dc.title | Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis | en_US |
dc.type | article | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.volume | 49 | en_US |
dc.identifier.startpage | 1827 | en_US |
dc.identifier.endpage | 1836 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | [Cevik, Mehtap; Susleyici, Belgin] Marmara Univ, Fac Arts & Sci, Dept Mol Biol, Istanbul, Turkey; [Namal, Esat; Dinc-Sener, Nur] Demiroglu Bilim Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey; [Iner-Koksal, Ulkuhan] Istanbul Bagcilar Training & Res Hosp, Istanbul, Turkey; [Karaalp, Atila] Marmara Univ, Sch Med, Dept Med Pharmacol, Istanbul, Turkey; [Ciftci, Cavlan] Demiroglu Bilim Univ, Fac Med, Dept Cardiol, Istanbul, Turkey | en_US |
dc.authorid | Karaalp, Atila/0000-0003-3382-9483 | |
dc.authorid | Cevik, Mehtap/0000-0001-8912-8307 | |
dc.identifier.pmid | 35076848 | en_US |
dc.identifier.scopus | 2-s2.0-85123472044 | en_US |
dc.identifier.wos | WOS:000746783200010 | en_US |
dc.authorscopusid | 57216620714 | |
dc.authorscopusid | 36667213900 | |
dc.authorscopusid | 57190187506 | |
dc.authorscopusid | 57225196358 | |
dc.authorscopusid | 6602210835 | |
dc.authorscopusid | 15821728300 | |
dc.authorscopusid | 57216623478 | |